Double hit on melanoma unlocks barrier to immunotherapy
Researchers at EPFL and UNIL have discovered a dangerous liaison between immune cells that limits the efficacy of immunotherapy in melanoma. But they also found a way to disrupt it.
Researchers at EPFL and UNIL have discovered a dangerous liaison between immune cells that limits the efficacy of immunotherapy in melanoma. But they also found a way to disrupt it.
